PDCD1 and non-Hodgkin lymphoma: Thus, treatment with immune checkpoint inhibitors targeting PD-1/PD-L1, either alone or in combination with other immune checkpoint inhibitors, can restore T cell effector function [14] and has emerged as a promising strategy for hematological malignancy therapy, particularly in patients with refractory Hodgkin lymphoma [15, 16], relapsed follicular lymphoma (FL) [17], and other aggressive non-Hodgkin lymphoma (NHL) [18, 19].